3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Breast
1
Conditions
Prostatic Neoplasms
4
Breast Neoplasms
4
Colonic Neoplasms
3
Rectal Neoplasms
2
Melanoma
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Myeloid, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Leukemia, Eosinophilic, Acute
2
Leukemia, Basophilic, Acute
2
Leukemia
2
Kidney Neoplasms
2
Wilms Tumor
1
Unspecified Childhood Solid Tumor, Protocol Specific
1
Tuberous Sclerosis
1
Thyroid Neoplasms
1
Spinal Cord Neoplasms
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Pediatric Solid Tumor
1
Paraganglioma
1
Pancreatic Neoplasms
1
Neoplastic Syndromes, Hereditary
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma, Cutaneous Malignant
1
Lymphangioleiomyomatosis
1
Interventions
pyrotinib
4
neratinib
2
tucatinib
1
trastuzumab deruxtecan
1
pertuzumab
1
Trastuzumab
1
Hospital Information Systems
1
Genetic Testing
1
Electronic Health Records
1
Blood Specimen Collection
1
Biopsy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
HER2-positive Breast Cancer
×
Genetic Testing
×
Clear all
NCT04638725
2022-08-03
SIGHER
Institut de cancérologie Strasbourg Europe
Recruiting
9,000 enrolled